These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 12424506)

  • 41. The population pharmacokinetics of digoxin in dogs with heart disease.
    Whittem T; Hogan D; Sisson D; Cooper T
    J Vet Pharmacol Ther; 2000 Aug; 23(4):261-3. PubMed ID: 11126326
    [No Abstract]   [Full Text] [Related]  

  • 42. Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha).
    Tankanow R; Tamer HR; Streetman DS; Smith SG; Welton JL; Annesley T; Aaronson KD; Bleske BE
    J Clin Pharmacol; 2003 Jun; 43(6):637-42. PubMed ID: 12817526
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A population pharmacokinetic analysis of the influence of nutritional status of digoxin in hospitalized Korean patients.
    Choi SA; Yun HY; Lee ES; Shin WG
    Clin Ther; 2014 Mar; 36(3):389-400. PubMed ID: 24612944
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cilomilast: pharmacokinetic and pharmacodynamic interactions with digoxin.
    Zussman BD; Kelly J; Murdoch RD; Clark DJ; Mbchb ; Schubert C; Collie H
    Clin Ther; 2001 Jun; 23(6):921-31. PubMed ID: 11440291
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Low-dose digoxin in patients with heart failure. Less toxic and at least as effective?
    van Veldhuisen DJ
    J Am Coll Cardiol; 2002 Mar; 39(6):954-6. PubMed ID: 11897435
    [No Abstract]   [Full Text] [Related]  

  • 46. Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer.
    Bonate PL; Cunningham CC; Gaynon P; Jeha S; Kadota R; Lam GN; Razzouk B; Rytting M; Steinherz P; Weitman S
    Cancer Chemother Pharmacol; 2011 Apr; 67(4):875-90. PubMed ID: 20582417
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Morning-evening administration time differences in digoxin kinetics in healthy young subjects.
    Erol K; Kiliç FS; Batu OS; Yildirim E
    Chronobiol Int; 2001 Sep; 18(5):841-9. PubMed ID: 11763991
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Do therapeutic doses of acarbose alter the pharmacokinetics of digoxin?
    Cohen E; Almog S; Staruvin D; Garty M
    Isr Med Assoc J; 2002 Oct; 4(10):772-5. PubMed ID: 12389338
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants.
    Devineni D; Manitpisitkul P; Vaccaro N; Bernard A; Skee D; Mamidi RN; Tian H; Weiner S; Stieltjes H; Sha S; Rothenberg P
    Int J Clin Pharmacol Ther; 2015 Jan; 53(1):41-53. PubMed ID: 25345427
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Digoxin population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens.
    Yukawa E; Mine H; Higuchi S; Aoyama T
    J Pharm Pharmacol; 1992 Sep; 44(9):761-5. PubMed ID: 1360530
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of SLCO4C1 Genotypes, Creatinine, and Spironolactone on Digoxin Population Pharmacokinetic Variables in Patients With Cardiac Insufficiency.
    Du P; Wang A; Ma Y; Jia A; Li Y; Li X
    Clin Ther; 2020 Sep; 42(9):1799-1810.e3. PubMed ID: 32798059
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Absorption of digoxin in severe right heart failure.
    Ohnhaus EE; Vozeh S; Nuesch E
    Eur J Clin Pharmacol; 1979 Mar; 15(2):115-20. PubMed ID: 374088
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Digoxin: use pattern in Estonia and bioavailability of the local market leader.
    Pähkla R; Irs A; Oselin K; Rootslane L
    J Clin Pharm Ther; 1999 Oct; 24(5):375-80. PubMed ID: 10583701
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Predictive performance of four pharmacokinetic methods for calculating digoxin dosage.
    el-Sayed YM
    J Clin Pharm Ther; 1995 Oct; 20(5):297-304. PubMed ID: 8576297
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An assessment of population-based and Bayesian methods to individualize digoxin doses shortly after the start of therapy for atrial fibrillation.
    Chrystyn H; Dean S
    J Clin Pharm Ther; 1991 Jun; 16(3):177-85. PubMed ID: 1869597
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Estimation of lithium clearance from routine clinical data in Egyptian bipolar patients. A population pharmacokinetic approach.
    ElDesoky ES; Kumar V; Alorainy MS; Hamdi MM; Derendorf H
    Int J Clin Pharmacol Ther; 2008 Dec; 46(12):617-26. PubMed ID: 19049695
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The hemodynamic and pharmacokinetic interactions between chronic use of oral levosimendan and digoxin in patients with NYHA Classes II-III heart failure.
    Harjola VP; Oikarinen L; Toivonen L; Jurkko R; Puttonen J; Sarapohja T; Sundberg S; Nieminen MS
    Int J Clin Pharmacol Ther; 2008 Aug; 46(8):389-99. PubMed ID: 18793580
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Some comments and suggestions concerning population pharmacokinetic modeling, especially of digoxin, and its relation to clinical therapy.
    Jelliffe RW
    Ther Drug Monit; 2012 Aug; 34(4):368-77. PubMed ID: 22735674
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effects of tegaserod (HTF 919) on the pharmacokinetics and pharmacodynamics of digoxin in healthy subjects.
    Zhou H; Horowitz A; Ledford PC; Hubert M; Appel-Dingemanse S; Osborne S; McLeod JF
    J Clin Pharmacol; 2001 Oct; 41(10):1131-9. PubMed ID: 11583482
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of lapatinib on oral digoxin absorption in patients.
    Koch KM; Smith DA; Botbyl J; Arya N; Briley LP; Cartee L; White JH; Beyer J; Dar MM; Chung HC; Chu Q; Bang YJ
    Clin Pharmacol Drug Dev; 2015 Nov; 4(6):449-53. PubMed ID: 27137717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.